Evaluation of Soluble PD-1 and PD-L1 in Iraqi Type 2 Diabetes Mellitus (T2DM) Patients with Chronic Toxoplasmosis
DOI:
https://doi.org/10.37506/mlu.v20i3.1467Keywords:
Toxoplasma gondii, chronic toxoplasmosis, T2DM, sPD-1 and sPDL-1Abstract
Toxoplasma gondii is an important opportunistic parasite in immunocompromised people. Globally, diabetes
mellitus is one of the most challenging public health burdens of the 21st century. Both toxoplasmosis and
diabetes are very common in Iraq and other countries. The main objective of the present study was to
investigate the sero- prevalence of the anti-Toxoplasma gondii IgG antibodies in Iraqi T2DM patients and
to clarify the role of soluble programmed death-1 (sPD-1) and ( sPD-L1) in Iraqi T2DM patients with
chronic toxoplasmosis. Enzyme Linked Immunosorbent Assay (ELISA) was used to detect anti- T. gondii
IgG antibodies in the sera of 180 patients with type 2 diabetes mellitus (T2DM) and 163 apparently healthy
controls. The results showed that 117(34%) samples of sera patients have been founded T2DM with
toxoplasmosis, 63(18%) samples have T2DM, 55(16%) cases have control toxoplasmosis (those patients
were had toxoplasmosis but showing no symptoms) and 108 (32%) cases samples were considered as a
control group without any infections. Sera (sPD-1 and sPDL-1) levels were determined by ELISA using a
quantitative sandwich enzyme immunoassay technique. The results showed that levels of sPD-1 and sPDL-1
levels were significantly higher in patients group than healthy subjects (P<0.01).